Diligence memo · auto-generated · as of July 2, 2026

Kopra Bio

Kopra Bio: limited disclosed financing to assess.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Kopra Bio operates in Biotech, based in San Francisco, CA, USA. Genetically engineered viruses that teach your immune system to kill…

Sub-sector tags: Gene Therapy, Synthetic Biology, Biotech, Therapeutics, Oncology.

Capital & rounds (filed)filed

Kopra Bio has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.

Valuation (modeled)modeled

No modeled valuation — too little disclosed financing to estimate one.

Financing rhythm & timingmixed

Not enough dated financing history to read a financing rhythm.

Comparablesmixed

Capital scale ranks ahead of 67% of Biotech peers (233 compared).

Modeled value ranks above 67% of those peers.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.